Toronto Dominion Bank
SABSW icon

Toronto Dominion Bank’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Toronto Dominion Bank’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$5 – 2251
2025
Q3 		$5 Buy
+200
New +$7 ﹤0.01% 1905

Other funds holding SABSW

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Toronto Dominion Bank's SABSW Position: Q4 2025 in Review

Toronto Dominion Bank sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2025, closing a stake of 200 shares — an estimated $5 sold.

Toronto Dominion Bank first reported a position in SABSW in Q3 2025 and held it in 1 quarter. The position peaked at $5 in Q3 2025. 7 funds tracked by Wall St. Rank hold SABSW as of Q4 2025.

  • Toronto Dominion Bank reported no remaining SAB Biotherapeutics Warrant position as of Q4 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 200 SAB Biotherapeutics Warrant shares in Q4 2025, an estimated $5.
  • Toronto Dominion Bank first reported a position in SAB Biotherapeutics Warrant in Q3 2025 and held it in 1 quarter.
  • Toronto Dominion Bank's SAB Biotherapeutics Warrant position peaked at $5 in Q3 2025.
  • 7 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2025.

Based on Toronto Dominion Bank's 13F filing for Q4 2025, filed 17 Feb 2026.